JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

In a report released today, Elmar Kraus from DZ BANK AG maintained a Hold rating on Novo Nordisk (0QIU – Research Report). The company’s shares ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...

Walmart steel cage match (although we would totally watch). Instead, Walmart gave its logo a makeover fit for modern times—at least that was the idea. But people, well, they have feelings.

I’m cautious about Novo Nordisk's stock in the short term due to the recent selloff momentum, which could bottom out if the FDA rejects its petition to restrict compounding alternatives.

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE:NVO) following recent industry developments and competitive insights. The firm said in a note ...